Table 2 Susceptibility of mycobacterial strains to CLA, CLO, and RIF at their concentrations in the MIC of CLA–CLO–RIF (RHB-104 active ingredients)
Organism | Source | MIC | Comparison analysis | |||||
|---|---|---|---|---|---|---|---|---|
CLA–CLO–RIF | CLA (63.3 %) | CLO (6.7 %) | RIF (30 %) | |||||
μg/mL | μg/mL | Susceptibility | μg/mL | Susceptibility | μg/mL | Susceptibility | ||
Clinical MAP strains | ||||||||
MAP UCF 3 | Tissue | 0.25 | 0.158 | R | 0.017 | R | 0.075 | R |
MAP UCF 4 | Tissue | 0.25 | 0.633 | R | 0.067 | R | 0.3 | R |
MAP UCF 5 | Tissue | 0.25 | 0.633 | R | 0.067 | R | 0.3 | R |
MAP UCF 7 | Tissue | 0.25 | 0.633 | R | 0.067 | R | 0.3 | R |
MAP UCF 8 | Tissue | 0.25 | 0.633 | R | 0.067 | R | 0.3 | R |
MAP Strain 1 | Milk | 0.25 | 0.633 | R | 0.067 | R | 0.3 | R |
MAP Strain 3 | Tissue | 0.25 | 0.633 | R | 0.067 | R | 0.3 | R |
MAP Strain 7 | Tissue | 0.25 | 0.633 | R | 0.067 | R | 0.3 | R |
MAP Strain 8B | Blood | 0.25 | 0.633 | R | 0.067 | R | 0.3 | R |
MAP MS 137 | Tissue | 4 | 2.532 | R | 0.268 | R | 1.2 | R |
MAP MS 185 | Tissue | 4 | 2.532 | R | 0.268 | R | 1.2 | R |
MAP Para 18 | ATCC 19698 | 0.25 | 0.633 | R | 0.067 | R | 0.3 | R |
MAP Ben | ATCC 43544 | 0.25 | 0.633 | R | 0.067 | R | 0.3 | R |
MAP Kay | ATCC C286 | 0.25 | 0.633 | R | 0.067 | R | 0.3 | R |
MAP Linda | ATCC 43015 | 0.25 | 0.633 | R | 0.067 | R | 0.3 | R |
Non-MAP strains | ||||||||
M. avium | ATCC 25291 | 4 | 2.532 | R | 0.268 | R | 1.2 | R |
M. avium JF 5 | Faeces | 4 | 2.532 | R | 0.268 | R | 1.2 | R |
M. avium JF 6 | Faeces | 4 | 2.532 | R | 0.268 | R | 1.2 | R |
M. avium JF 8 | Blood | 4 | 2.532 | R | 0.268 | R | 1.2 | R |
M. intracellulare LM1-A | Sputum | 4 | 3.798 | R | 0.402 | R | 1.8 | R |
M-Smegmatis | ATCC 27199 | 6 | 3.798 | R | 0.402 | R | 1.8 | R |
M. chelonae subsp. chelonea | >10a | 6.33 | R | 0.67 | R | 3 | R | |
M. fortuitum subsp. fortuitum | >10a | 6.33 | R | 0.67 | R | 3 | R | |